175 related articles for article (PubMed ID: 31189644)
1. High Numbers of Circulating CD57
Muntasell A; Servitja S; Cabo M; Bermejo B; Pérez-Buira S; Rojo F; Costa-García M; Arpí O; Moraru M; Serrano L; Tusquets I; Martínez MT; Heredia G; Vera A; Martínez-García M; Soria L; Comerma L; Santana-Hernández S; Eroles P; Rovira A; Vilches C; Lluch A; Albanell J; López-Botet M
Cancer Immunol Res; 2019 Aug; 7(8):1280-1292. PubMed ID: 31189644
[TBL] [Abstract][Full Text] [Related]
2. NK Cell Infiltrates and HLA Class I Expression in Primary HER2
Muntasell A; Rojo F; Servitja S; Rubio-Perez C; Cabo M; Tamborero D; Costa-García M; Martínez-Garcia M; Menéndez S; Vazquez I; Lluch A; Gonzalez-Perez A; Rovira A; López-Botet M; Albanell J
Clin Cancer Res; 2019 Mar; 25(5):1535-1545. PubMed ID: 30523021
[TBL] [Abstract][Full Text] [Related]
3. Polyfunctional KLRG-1
Ramello MC; Núñez NG; Tosello Boari J; Bossio SN; Canale FP; Abrate C; Ponce N; Del Castillo A; Ledesma M; Viel S; Richer W; Sedlik C; Tiraboschi C; Muñoz M; Compagno D; Gruppi A; Acosta Rodríguez EV; Piaggio E; Montes CL
Front Immunol; 2021; 12():713132. PubMed ID: 34386013
[TBL] [Abstract][Full Text] [Related]
4. CD16
Frazao A; Messaoudene M; Nunez N; Dulphy N; Roussin F; Sedlik C; Zitvogel L; Piaggio E; Toubert A; Caignard A
Cancer Immunol Res; 2019 Feb; 7(2):208-218. PubMed ID: 30514793
[TBL] [Abstract][Full Text] [Related]
5. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
6. NKG2C(+)CD57(+) Natural Killer Cell Expansion Parallels Cytomegalovirus-Specific CD8(+) T Cell Evolution towards Senescence.
Heath J; Newhook N; Comeau E; Gallant M; Fudge N; Grant M
J Immunol Res; 2016; 2016():7470124. PubMed ID: 27314055
[TBL] [Abstract][Full Text] [Related]
7. Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
Muraro E; Comaro E; Talamini R; Turchet E; Miolo G; Scalone S; Militello L; Lombardi D; Spazzapan S; Perin T; Massarut S; Crivellari D; Dolcetti R; Martorelli D
J Transl Med; 2015 Jun; 13():204. PubMed ID: 26116238
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer.
Villegas FR; Coca S; Villarrubia VG; Jiménez R; Chillón MJ; Jareño J; Zuil M; Callol L
Lung Cancer; 2002 Jan; 35(1):23-8. PubMed ID: 11750709
[TBL] [Abstract][Full Text] [Related]
9. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells.
Ohkawa T; Seki S; Dobashi H; Koike Y; Habu Y; Ami K; Hiraide H; Sekine I
Immunology; 2001 Jul; 103(3):281-90. PubMed ID: 11454057
[TBL] [Abstract][Full Text] [Related]
10. Differential regulation of human monocytes and NK cells by antibody-opsonized tumors.
Yin J; Albers AJ; Smith TS; Riddell GT; Richards JO
Cancer Immunol Immunother; 2018 Aug; 67(8):1239-1250. PubMed ID: 29855696
[TBL] [Abstract][Full Text] [Related]
11. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
[TBL] [Abstract][Full Text] [Related]
12. Circulating and Tumor-Infiltrating NK Cells From Clear Cell Renal Cell Carcinoma Patients Exhibit a Predominantly Inhibitory Phenotype Characterized by Overexpression of CD85j, CD45, CD48 and PD-1.
Ziblat A; Iraolagoitia XLR; Nuñez SY; Torres NI; Secchiari F; Sierra JM; Spallanzani RG; Rovegno A; Secin FP; Fuertes MB; Domaica CI; Zwirner NW
Front Immunol; 2021; 12():681615. PubMed ID: 34149719
[TBL] [Abstract][Full Text] [Related]
13. The anti-B7-H4 checkpoint synergizes trastuzumab treatment to promote phagocytosis and eradicate breast cancer.
Hu X; Liu Y; Zhang X; Kong D; Kong J; Zhao D; Guo Y; Sun L; Chu L; Liu S; Hou X; Ren F; Zhao Y; Lu C; Zhai D; Yuan X
Neoplasia; 2020 Nov; 22(11):539-553. PubMed ID: 32966956
[TBL] [Abstract][Full Text] [Related]
14. Expression of NK Cell Surface Receptors in Breast Cancer Tissue as Predictors of Resistance to Antineoplastic Treatment.
Garcia-Chagollan M; Carranza-Torres IE; Carranza-Rosales P; Guzmán-Delgado NE; Ramírez-Montoya H; Martínez-Silva MG; Mariscal-Ramirez I; Barrón-Gallardo CA; Pereira-Suárez AL; Aguilar-Lemarroy A; Jave-Suárez LF
Technol Cancer Res Treat; 2018 Jan; 17():1533033818764499. PubMed ID: 29558872
[TBL] [Abstract][Full Text] [Related]
15. The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low-Expressing Cancer
Dreyer TF; Kuhn S; Stange C; Heithorst N; Schilling D; Jelsma J; Sievert W; Seitz S; Stangl S; Hapfelmeier A; Noske A; Wege AK; Weichert W; Ruland J; Schmitt M; Dorn J; Kiechle M; Reuning U; Magdolen V; Multhoff G; Bronger H
Cancer Immunol Res; 2021 Jul; 9(7):779-789. PubMed ID: 33906866
[TBL] [Abstract][Full Text] [Related]
16. Increased Expression of TIGIT/CD57 in Peripheral Blood/Bone Marrow NK Cells in Patients with Chronic Myeloid Leukemia.
Yao D; Xu L; Liu L; Zeng X; Zhong J; Lai J; Zheng R; Jin Z; Chen S; Zha X; Huang X; Lu Y
Biomed Res Int; 2020; 2020():9531549. PubMed ID: 33102599
[TBL] [Abstract][Full Text] [Related]
17. Ranitidine Inhibition of Breast Tumor Growth Is B Cell Dependent and Associated With an Enhanced Antitumor Antibody Response.
Rogers D; Vila-Leahey A; Pessôa AC; Oldford S; Marignani PA; Marshall JS
Front Immunol; 2018; 9():1894. PubMed ID: 30158936
[TBL] [Abstract][Full Text] [Related]
18. Robust 8-color flow cytometry panel reveals enhanced effector function of NKG2C
Nerreter T; Zeiß S; Herrmann T; Einsele H; Seggewiss-Bernhardt R
Immunobiology; 2017 May; 222(5):719-725. PubMed ID: 28139257
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of Tumor-Infiltrating Natural Killer Cells in Solid Tumors: A Systematic Review and Meta-Analysis.
Zhang S; Liu W; Hu B; Wang P; Lv X; Chen S; Shao Z
Front Immunol; 2020; 11():1242. PubMed ID: 32714321
[No Abstract] [Full Text] [Related]
20. Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer.
Hori A; Shimoda M; Naoi Y; Kagara N; Tanei T; Miyake T; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res; 2019 Aug; 21(1):88. PubMed ID: 31387614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
